LTR Pharma Limited (ASX:LTP), a company dedicated to advancing men’s health, has proudly announced the commencement of patient recruitment for a pivotal bioequivalence clinical study of its innovative nasal spray treatment for Erectile Dysfunction (ED), named SPONTAN. This landmark study aims to evaluate the relative bioavailability of Vardenafil via SPONTAN nasal spray compared to the traditional oral delivery through Vardenafil tablets, a commonly used PDE5 inhibitor.

ED affects a significant portion of the male population worldwide, with current treatments often facing high discontinuation rates. LTR Pharma’s SPONTAN nasal spray is designed to address these challenges by offering a fast-acting, on-demand solution. The company, in collaboration with Southern Star Research, its Contract Research Organisation (CRO) partner, intends to redefine treatment standards for ED, potentially enhancing the lives and relationships of men globally.

The study is structured as a single-dose, randomized, open-label, two-treatment, two-period crossover study comparing SPONTAN nasal spray with Vardenafil tablets under fasting conditions. Healthy adult male volunteers participating in the study will undergo a rigorous screening process, with the study being conducted at a site in Sydney managed by Scientia Clinical Research. The entire duration of participant involvement is estimated at around four weeks, including screening, with the aim of gathering data to support New Drug Applications (NDA) to both the FDA and the TGA.

With the successful completion of the study, LTR Pharma plans to utilize the data in its regulatory submissions, marking a significant step towards commercialization and clinical application. The study not only showcases LTR Pharma’s commitment to fulfilling its clinical and commercial milestones but also highlights the potential of SPONTAN to disrupt the current ED treatment market.

Experts in the field, including LTR Pharma’s Scientific and Clinical Advisor, Professor Eric Chung, express enthusiasm for the study’s potential to offer new insights into ED treatment. Furthermore, the collaboration with Southern Star Research and Scientia Clinical Research underscores the importance of this trial in addressing unmet needs in men’s health.

LTR Pharma encourages eligible individuals to participate in this groundbreaking study, emphasizing the role of public involvement in advancing medical research. The company’s efforts, supported by its recent achievements in meeting FDA requirements for pivotal trials, signal a promising future for SPONTAN and its impact on men’s health.

As LTR Pharma advances towards regulatory approval and commercial scale-up, the success of the SPONTAN nasal spray could herald a new era in ED treatment, offering hope and improved quality of life for many.

  Erectile Dysfunction, Eric Chung, LTR Pharma, PDE5 inhibitor, SPONTAN, SPONTAN nasal spray, Vardenafil